ResearcherRoyal Marsden NHS Foundation TrustNo recent work listed
David J. Watkins
Matched on ORCID iD 0000-0003-0212-1765; OpenAlex author ID A5036429011, A5077300810. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper
Papers 7
- Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
- Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
- Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
- miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… Co-author DOI 10.18632/oncotarget.7208↗
- FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Co-author DOI 10.1016/j.clcc.2014.09.005↗
- The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancre… Co-author DOI 10.1016/j.ejca.2014.02.003↗
- A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr317↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ian Chau · 5 shared papers, 2012–2021 · strength 0.25
- Paper Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. DOI 10.1038/s41467-021-27099-6↗
- Paper miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic ca… DOI 10.18632/oncotarget.7208↗
- Paper FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. DOI 10.1016/j.clcc.2014.09.005↗
- David Cunningham · 5 shared papers, 2012–2021 · strength 0.25
- Paper Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. DOI 10.1038/s41467-021-27099-6↗
- Paper miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic ca… DOI 10.18632/oncotarget.7208↗
- Paper FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. DOI 10.1016/j.clcc.2014.09.005↗
- Naureen Starling · 4 shared papers, 2012–2021 · strength 0.20
- Paper Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. DOI 10.1038/s41467-021-27099-6↗
- Paper miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic ca… DOI 10.18632/oncotarget.7208↗
- Paper The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erl… DOI 10.1016/j.ejca.2014.02.003↗
- Andrew H. Ko · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Syed Farhan Zafar · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Fernando Rivera Herrero · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Uwe Pelzer · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Hana Algül · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Johanna C. Bendell · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Madappa N. Kundranda · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- J. Marc Pipas · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Matteo Fassan · 2 shared papers, 2016–2021 · strength 0.13
- Paper Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. DOI 10.1038/s41467-021-27099-6↗
- Paper miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic ca… DOI 10.18632/oncotarget.7208↗
- Chiara Braconi · 2 shared papers, 2016–2021 · strength 0.13
- Paper Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. DOI 10.1038/s41467-021-27099-6↗
- Paper miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic ca… DOI 10.18632/oncotarget.7208↗
- Khurum Hayat Khan · 2 shared papers, 2014–2016 · strength 0.10
- Paper miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic ca… DOI 10.18632/oncotarget.7208↗
- Paper FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. DOI 10.1016/j.clcc.2014.09.005↗
- Maria C. Previdi · 1 shared paper, 2021 · strength 0.08
- Anguraj Sadanandam · 1 shared paper, 2021 · strength 0.08
- Jens Claus Hahne · 1 shared paper, 2021 · strength 0.08
- Pietro Carotenuto · 1 shared paper, 2021 · strength 0.08
- Kate Young · 1 shared paper, 2021 · strength 0.08
- Nigel Balfour Jamieson · 1 shared paper, 2021 · strength 0.08
- Francesco Sclafani · 1 shared paper, 2021 · strength 0.08
- David Kuang-Fu Chang · 1 shared paper, 2021 · strength 0.08
- Andrew Victor Biankin · 1 shared paper, 2021 · strength 0.08
- Aldo Scarpa Scarpa · 1 shared paper, 2021 · strength 0.08
- M. Hawkins · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.